A Study to Characterize the Clinical Course of Pregnant Women and Children at High Risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn

Completed

Conditions studied: Early Onset Severe Hemolytic Disease of the Fetus and Newborn (EOS-HDFN), Erythroblastosis, Fetal

In brief

The primary purpose of the study is to characterize the current standard of care, clinical course, and outcomes of pregnant women and their offspring at high risk for early onset severe hemolytic disease of the fetus and newborn (EOS-HDFN).

Key facts

Study ID: NCT03755128
Run by: Janssen Research & Development, LLC
People needed: 17
Starts: 2019-01-16
Expected to finish: 2023-09-22
Last updated by the study team: 2025-09-12

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

Where it is running

Columbia University Medical Center — New York, New York, United States
University of Cincinnati — Cincinnati, Ohio, United States
Oregon Health and Science University — Portland, Oregon, United States
UPMC — Pittsburgh, Pennsylvania, United States
University of Utah — Salt Lake City, Utah, United States
Liverpool Hospital — Liverpool, Australia
The Royal Women's Hospital — Parkville, Australia
Universitair Ziekenhuis Leuven — Leuven, Belgium
The University of British Columbia — Vancouver, British Columbia, Canada
Mount Sinai Hospital — Toronto, Ontario, Canada
Centre Hospitalier Sainte Justine — Montreal, Quebec, Canada
Justus-Liebig-Universität Gießen, Kinderherzzentrum — Giessen, Germany
Leiden University Medical Center — Leiden, Netherlands
Hosp Clinic de Barcelona — Barcelona, Spain
Hosp. Univ. San Cecilio — Granada, Spain
Karolinska Universitetssjukhuset Huddinge — Stockholm, Sweden
Queen Elizabeth Hospital — Edgbaston, United Kingdom
University College London Hospitals NHSFT — London, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.